Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192–207.
Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.
Carter G, Meyerson B, Rivers P, Crosby R, Lawrence C, Cope SD, et al. Living at the confluence of stigmas: PrEP awareness and feasibility among people who inject drugs in two predominantly rural states. AIDS Behav. 2021;25(10):3085–96.
McFarland W, Lin J, Santos GM, Arayasirikul S, Raymond HF, Wilson E. Low PrEP awareness and use among people who inject drugs, San Francisco, 2018. AIDS Behav. 2020;24(5):1290–3.
Sherman SG, Schneider KE, Park JN, Allen ST, Hunt D, Chaulk CP, et al. PrEP awareness, eligibility, and interest among people who inject drugs in Baltimore, Maryland. Drug Alcohol Depend. 2019;1(195):148–55.
Walters SM, Kral AH, Simpson KA, Wenger L, Bluthenthal RN. HIV pre-exposure prophylaxis prevention awareness, willingness, and perceived barriers among people who inject drugs in los angeles and San Francisco, CA, 2016–2018. Subst Use Misuse. 2020;55(14):2409–19.
Allen ST, O’Rourke A, White RH, Smith KC, Weir B, Lucas GM, et al. Barriers and facilitators to PrEP use among people who inject Drugs in rural appalachia: a qualitative study. AIDS Behav. 2020;24(6):1942–50.
Surratt HL, Yeager HJ, Adu A, González EA, Nelson EO, Walker T. Pre-exposure prophylaxis barriers, facilitators and unmet need among rural people who inject drugs: a qualitative examination of syringe service program client perspectives. Frontiers in Psychiatry [Internet]. 2022 [cited 2022 Jun 9];13. Available from: https://www.frontiersin.org/article/https://doi.org/10.3389/fpsyt.2022.905314.
Biello KB, Bazzi AR, Mimiaga MJ, Biancarelli DL, Edeza A, Salhaney P, et al. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs. Harm Reduct J. 2018;15(1):55.
Walters SM, Frank D, Van Ham B, Jaiswal J, Muncan B, Earnshaw V, et al. PrEP care continuum engagement among persons who inject drugs: rural and urban differences in stigma and social infrastructure. AIDS Behav. 2022;26(4):1308–20.
Edelman EJ, Moore BA, Calabrese SK, Berkenblit G, Cunningham C, Patel V, et al. Primary care physicians’ willingness to prescribe HIV pre-exposure prophylaxis for people who inject drugs. AIDS Behav. 2017;21(4):1025–33.
Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A, Van Velzen E, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(1):235–48.
Frost T, Deutsch S, Brown S, Lemien E, Cunningham CO, Fox AD. “We’ll be able to take care of ourselves” - a qualitative study of client attitudes toward implementing buprenorphine treatment at syringe services programs. Subst Abus. 2021;42(4):983–9.
Hodder SL, Feinberg J, Strathdee SA, Shoptaw S, Altice FL, Ortenzio L, et al. The opioid crisis and HIV in the USA: deadly synergies. Lancet. 2021;397(10279):1139–50.
Broz D, Carnes N, Chapin-Bardales J, Des Jarlais DC, Handanagic S, Jones CM, et al. Syringe services programs’ role in ending the HIV epidemic in the U.S.: why we cannot do it without them. Am J Prev Med. 2021;61(5, Supplement 1):S118–29.
Darke S, Hall W. Heroin overdose: research and evidence-based intervention. J Urban Health. 2003;80(2):189–200.
Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;26(357): j1550.
MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. The BMJ [Internet]. 2012 [cited 2022 Nov 2];345. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489107/.
Centers for Disease Control and Prevention. HIV among people who inject drugs | HIV by Group | HIV/AIDS | CDC [Internet]. 2022 [cited 2022 Nov 2]. Available from: https://www.cdc.gov/hiv/group/hiv-idu.html.
Sullivan LE, Moore BA, Chawarski MC, Pantalon MV, Barry D, O’Connor PG, et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat. 2008;35(1):87–92.
Woody GE, Bruce D, Korthuis PT, Chhatre S, Poole S, Hillhouse M, et al. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. JAIDS J Acquir Immune Defic Syndr. 2014;66(3):288–93.
Centers for Disease Control and Prevention. HIV infection risk, prevention, and testing behaviors among persons who inject drugs—National HIV behavioral surveillance: injection drug use, 23 U.S. Cities, 2018 [Internet]. 2020 Feb [cited 2022 Jun 9]. (HIV Surveillance Special Report). Report No.: 24. Available from: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.
Hewell VM, Vasquez AR, Rivkin ID. Systemic and individual factors in the buprenorphine treatment-seeking process: a qualitative study. Subst Abuse Treat Prev Policy. 2017;12(1):3.
Madden EF. Intervention stigma: How medication-assisted treatment marginalizes patients and providers. Soc Sci Med. 2019;1(232):324–31.
Cicero TJ, Ellis MS, Chilcoat HD. Understanding the use of diverted buprenorphine. Drug Alcohol Depend. 2018;1(193):117–23.
Fox AD, Chamberlain A, Sohler NL, Frost T, Cunningham CO. Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants. J Subst Abuse Treat. 2015;48(1):112–6.
Corry B, Underwood N, Cremer LJ, Rooks-Peck CR, Jones C. County-level sociodemographic differences in availability of two medications for opioid use disorder: United States, 2019. Drug Alcohol Depend. 2022;1(236): 109495.
Beetham T, Saloner B, Wakeman SE, Gaye M, Barnett ML. Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality. Ann Intern Med. 2019;171(1):1–9.
Jakubowski A, Norton BL, Hayes BT, Gibson BE, Fitzsimmons C, Stern LS, et al. Low-threshold Buprenorphine treatment in a syringe services program: program description and outcomes. J Addict Med. 2021.
Hood JE, Banta-Green CJ, Duchin JS, Breuner J, Dell W, Finegood B, et al. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: lessons learned from Seattle, Washington. Subst Abus. 2020;41(3):356–64.
Hill K, Nussdorf L, Mount JD, Silk R, Gross C, Sternberg D, et al. Initiation of low-threshold buprenorphine in nontreatment seeking patients with opioid use disorder engaged in hepatitis C treatment. J Addict Med. 2022;16(1):10–7.
Stancliff S, Joseph H, Fong C, Furst T, Comer SD, Roux P. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations. J Addict Dis. 2012;31(3):278–87.
Bachhuber MA, Thompson C, Prybylowski A, Benitez J, Mazzella S, Barclay D. Description and outcomes of a buprenorphine maintenance treatment program integrated within prevention point Philadelphia, an urban syringe exchange program. Subst Abus. 2018;39(2):167–72.
Roth AM, Tran NK, Felsher M, Gadegbeku AB, Piecara B, Fox R, et al. Integrating HIV preexposure prophylaxis with community-based syringe services for women who inject drugs: results from the project SHE demonstration study. J Acquir Immune Defic Syndr. 2021;86(3):e61-70.
Carter J, Zevin B, Lum PJ. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. Addict Sci Clin Pract. 2019;14(1):20.
North Carolina Department of Health and Human Services. NC safer syringe initiative annual report, 2020–2021 [Internet]. Raleigh, NC; [cited 2022 Apr 26]. Available from: https://www.ncdhhs.gov/media/13767/download?attachment
Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. JAMA. 2019;321(9):844–5.
North Carolina Department of Health and Human Services. Opioid and substance use action plan data dashboard [Internet]. [Cited 2022 Apr 4]. Available from: https://www.ncdhhs.gov/opioid-and-substance-use-action-plan-data-dashboard.
Eibl JK, Gauthier G, Pellegrini D, Daiter J, Varenbut M, Hogenbirk JC, et al. The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting. Drug Alcohol Depend. 2017;1(176):133–8.
King VL, Stoller KB, Kidorf M, Kindbom K, Hursh S, Brady T, et al. Assessing the effectiveness of an internet-based videoconferencing platform for delivering intensified substance abuse counseling. J Subst Abuse Treat. 2009;36(3):331–8.
King VL, Brooner RK, Peirce JM, Kolodner K, Kidorf MS. A randomized trial of Web-based videoconferencing for substance abuse counseling. J Subst Abuse Treat. 2014;46(1):36–42.
Zheng W, Nickasch M, Lander L, Wen S, Xiao M, Marshalek P, et al. Treatment outcome comparison between telepsychiatry and face-to-face buprenorphine medication-assisted treatment for opioid use disorder: a 2-year retrospective data analysis. J Addict Med. 2017;11(2):138–44.
Snoswell CL, Comans TA. Does the choice between a telehealth and an in-person appointment change patient attendance? Telemed J E Health. 2021;27(7):733–8.
Childs AW, Bacon SM, Klingensmith K, Li L, Unger A, Wing AM, et al. Showing up is half the battle: the impact of telehealth on psychiatric appointment attendance for hospital-based intensive outpatient services during COVID-19. Telemed J E Health. 2021;27(8):835–42.
Choi Y, Perry B, Chen H, Corneli A, Des Marais A, Meade C, et al. Providing medication for opioid use disorder and pre-exposure prophylaxis for HIV prevention through syringe services programs in North Carolina. Poster presented at: 2022 Apr 18, Atlanta, GA.
Chen H, Choi Y, Corneli A, Des Marais A, Perry B, Poley S, et al. Providing a resource: telemedicine at needle exchanges to reach underserved people (PARTNER UP). In: Virtual conference; 2021.
Sandelowski M. Whatever happened to qualitative description? Res Nurs Health. 2000;23(4):334–40.
Sandelowski M. What’s in a name? Qual Descr Revisit Res Nurs Health. 2010;33(1):77–84.
Patton MQ. Qualitative research and evaluation methods. Thousand Oaks, CA: Sage Publications; 2002.
Davis FD, Bagozzi RP, Warshaw PR. User acceptance of computer technology: a comparison of two theoretical models. Manag Sci. 1989;35(8):982–1003.
Portz JD, Bayliss EA, Bull S, Boxer RS, Bekelman DB, Gleason K, et al. Using the technology acceptance model to explore user experience, intent to use, and use behavior of a patient portal among older adults with multiple chronic conditions: descriptive qualitative study. J Med Internet Res. 2019;21(4): e11604.
Kamal SA, Shafiq M, Kakria P. Investigating acceptance of telemedicine services through an extended technology acceptance model (TAM). Technol Soc. 2020;60: 101212.
Bunnell BE, Barrera JF, Paige SR, Turner D, Welch BM. Acceptability of telemedicine features to promote its uptake in practice: a survey of community telemental health providers. IJERPH. 2020;17(22):8525.
Holtz B, Mitchell K, Hirko K, Ford S. Using the technology acceptance model to characterize barriers and opportunities of telemedicine in rural populations: survey and interview study. JMIR Form Res. 2022;6(4): e35130.
Rönnby S, Lundberg O, Fagher K, Jacobsson J, Tillander B, Gauffin H, et al. mHealth self-report monitoring in competitive middle- and long-distance runners: qualitative study of long-term use intentions using the technology acceptance model. JMIR Mhealth Uhealth. 2018;6(8): e10270.
Guest G, MacQueen KM, Namey EE. Applied thematic analysis. Thousand Oaks: SAGE Publications; 2012.
QSR International Pyt Ltd. Nvivo 12. 2015.
Khati A, Altice FL, Vlahov D, Eger WH, Lee J, Bohonnon T, et al. Nurse practitioner-led integrated rapid access to HIV prevention for people who inject drugs (iRaPID): protocol for a pilot randomized controlled trial. JMIR Res Protoc. 2022;11(10): e42585.